Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Current Opinion in HIV and AIDS|August 1, 2020
Engineering antibody-based molecules for HIV treatment and cureMarina Tuyishime, Guido FerrariBioorganic & Medicinal Chemistry Letters|November 5, 2015
Core chemotype diversification in the HIV-1 entry inhibitor class using field-based bioisosteric replacementMarina Tuyishime, Rae Lawrence, Simon CocklinJournal of Virology|March 30, 2018
Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal <i>Ex Vivo</i>Carolina Garrido, Maria Abad-Fernandez, Marina Tuyishime, et al.Frontiers in Immunology|September 6, 2021
Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART<sup>®</sup> MoleculesMarina Tuyishime, Amir Dashti, Katelyn Faircloth, et al.Immunogenetics|July 29, 2022
Functional consequences of allotypic polymorphisms in human immunoglobulin G subclassesAndrew R Crowley, Simone I Richardson, Marina Tuyishime, et al.The Journal of Clinical Investigation|June 26, 2020
Improved killing of HIV-infected cells using three neutralizing and non-neutralizing antibodiesMarina Tuyishime, Carolina Garrido, Shalini Jha, et al.Vaccines|September 28, 2021
Incorporating the Cluster A and V1V2 Targets into a Minimal Structural Unit of the HIV-1 Envelope to Elicit a Cross-Clade Response with Potent Fc-Effector FunctionsRebekah Sherburn, William D Tolbert, Suneetha Gottumukkala, et al.Bioorganic & Medicinal Chemistry Letters|December 3, 2014
Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacementMarina Tuyishime, Matt Danish, Amy Princiotto, et al.AIDS (London, England)|November 14, 2025
Resistance to broadly neutralizing antibodies in perinatally infected infants from a Clade C HIV cohort in MozambiqueLesley R de Armas, Marina Tuyishime, J Shawn Justement, et al.Plos Pathogens|February 25, 2020
Hinge length contributes to the phagocytic activity of HIV-specific IgG1 and IgG3 antibodiesThach H Chu, Andrew R Crowley, Iara Backes, et al.Pageof 3